Gafisa S.A. (BVMF:GFSA3)
Brazil · Delayed Price · Currency is BRL 15.31
+0.36 (2.41%)
Aug 6, 2025, 4:45 PM GMT-3
Regulus Therapeutics Income Statement
Financials in millions BRL. Fiscal year is January - December.
Millions BRL. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2020 |
| 985.46 | 1,012 | 1,104 | 1,136 | 818.31 | 884.05 | Upgrade | |
Revenue Growth (YoY) | -7.45% | -8.26% | -2.86% | 38.82% | -7.44% | 120.75% | Upgrade |
Cost of Revenue | 1,041 | 1,067 | 1,150 | 982.93 | 650.91 | 702.82 | Upgrade |
Gross Profit | -55.18 | -54.33 | -46.45 | 153.07 | 167.4 | 181.22 | Upgrade |
Selling, General & Admin | 137.77 | 144.01 | 153.03 | 173.05 | 167.63 | 110.55 | Upgrade |
Other Operating Expenses | -96.24 | -125.98 | -135.45 | 67.37 | -39.35 | 56.46 | Upgrade |
Operating Expenses | 56.24 | 32.01 | 39.2 | 272.1 | 149.17 | 175.28 | Upgrade |
Operating Income | -111.42 | -86.33 | -85.65 | -119.03 | 18.23 | 5.94 | Upgrade |
Interest Expense | -110.33 | -87.2 | -100.81 | -140.58 | -40.91 | -101.53 | Upgrade |
Interest & Investment Income | 8 | 9.81 | 16.65 | 210.48 | 22.59 | 28.54 | Upgrade |
Earnings From Equity Investments | -1.25 | -14.45 | 18.32 | -12.08 | 36.19 | - | Upgrade |
Other Non Operating Income (Expenses) | 76.71 | 106.83 | -28.21 | - | -69.11 | - | Upgrade |
EBT Excluding Unusual Items | -138.3 | -71.35 | -179.7 | -61.22 | -33.01 | -67.05 | Upgrade |
Gain (Loss) on Sale of Investments | 10.68 | 20.74 | 98.35 | - | 42.85 | - | Upgrade |
Asset Writedown | 85.07 | 85.07 | - | - | 41.24 | - | Upgrade |
Legal Settlements | -52.48 | -39.18 | -66.01 | - | -60.47 | - | Upgrade |
Other Unusual Items | - | - | - | - | 175.44 | - | Upgrade |
Pretax Income | -95.02 | -4.72 | -147.35 | -61.22 | 166.04 | -67.05 | Upgrade |
Income Tax Expense | -54.97 | 36.01 | 45.97 | 21.96 | 84.99 | 7.61 | Upgrade |
Earnings From Continuing Operations | -40.06 | -40.72 | -193.33 | -83.17 | 81.05 | -74.66 | Upgrade |
Earnings From Discontinued Operations | 0.64 | - | -2.15 | -0.02 | - | - | Upgrade |
Net Income to Company | -39.42 | -40.72 | -195.47 | -83.19 | 81.05 | -74.66 | Upgrade |
Minority Interest in Earnings | 0.15 | 0.15 | 0.16 | 0.02 | 0.21 | 0.48 | Upgrade |
Net Income | -39.27 | -40.58 | -195.31 | -83.17 | 81.26 | -74.18 | Upgrade |
Net Income to Common | -39.27 | -40.58 | -195.31 | -83.17 | 81.26 | -74.18 | Upgrade |
Shares Outstanding (Basic) | 5 | 5 | 3 | 2 | 2 | 1 | Upgrade |
Shares Outstanding (Diluted) | 5 | 5 | 3 | 2 | 2 | 1 | Upgrade |
Shares Change (YoY) | 54.89% | 56.45% | 58.71% | 12.65% | 112.86% | 221.53% | Upgrade |
EPS (Basic) | -7.93 | -8.73 | -65.75 | -44.44 | 49.41 | -95.04 | Upgrade |
EPS (Diluted) | -8.66 | -8.74 | -65.76 | -44.44 | 48.96 | -95.04 | Upgrade |
Free Cash Flow | 31.58 | 148.68 | 117.68 | -219.94 | -317.34 | -469.64 | Upgrade |
Free Cash Flow Per Share | 6.38 | 31.99 | 39.62 | -117.52 | -191.00 | -601.70 | Upgrade |
Gross Margin | -5.60% | -5.37% | -4.21% | 13.47% | 20.46% | 20.50% | Upgrade |
Operating Margin | -11.31% | -8.53% | -7.76% | -10.48% | 2.23% | 0.67% | Upgrade |
Profit Margin | -3.98% | -4.01% | -17.70% | -7.32% | 9.93% | -8.39% | Upgrade |
Free Cash Flow Margin | 3.21% | 14.69% | 10.66% | -19.36% | -38.78% | -53.12% | Upgrade |
EBITDA | -96.71 | -72.36 | -64.04 | -84.33 | 39.12 | 14.22 | Upgrade |
EBITDA Margin | -9.81% | -7.15% | -5.80% | -7.42% | 4.78% | 1.61% | Upgrade |
D&A For EBITDA | 14.71 | 13.98 | 21.61 | 34.7 | 20.89 | 8.28 | Upgrade |
EBIT | -111.42 | -86.33 | -85.65 | -119.03 | 18.23 | 5.94 | Upgrade |
EBIT Margin | -11.31% | -8.53% | -7.76% | -10.48% | 2.23% | 0.67% | Upgrade |
Effective Tax Rate | - | - | - | - | 51.19% | - | Upgrade |
Revenue as Reported | 985.46 | 1,012 | 1,104 | 1,136 | 818.31 | 884.05 | Upgrade |
Updated Nov 13, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.